Telomerase structure paves the way for new cancer therapies

Future Oncology

Volumn 5, Issue 2, 2009, Pages 163-167

  Skordalakes, Emmanuel ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Aging; Cancer; Telomerase; Telomeres

Indexed keywords

ANTINEOPLASTIC AGENT; PEPTIDE VACCINE; TELOMERASE;

AGING; ARTICLE; CANCER CELL; CELL DIVISION; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; DRUG DESIGN; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; STRUCTURE ANALYSIS; TELOMERE; ANIMAL; CELL AGING; CHEMISTRY; ENZYMOLOGY; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL AGING; DRUG DESIGN; HUMANS; NEOPLASMS; TELOMERASE;

EID: 66349131929     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.5.2.163     Document Type: Article

References (72)

1. Blackburn EH: The molecular structure of centromeres and telomeres. Annu. Rev. Biochem. 53, 163-194 (1984).
2. Cavalier Smith T. Palindromic base sequences and replication of eukaryote chromosome ends. Nature 250(5466) 467-470 (1974).
3. Levy MZ et al.: Telomere end-replication problem and cell aging. J. Mol. Biol. 225(4), 951-960 (1992).
4. Lingner J, Cooper JP, Cech TR: Telomerase and DNA end replication: no longer a lagging strand problem? Science 269 (5230), 1533-1534 (1995).
5. Ohki R, Tsurimoto T, Ishikawa F: In vitro reconstitution of the end replication problem. Mol. Cell. Biol. 21(17), 5753-5766 (2001).
6. Lundblad V, The end replication problem: more than one solution. Nat. Med. 3(11), 1198-1199 (1997).
7. Cech TR, Lingner J: Telomerase and the chromosome end replication problem. Ciba. Found, Symp. 211,20-28; discussion 28-34 (1997).
8. Telomerase: the end-replication problem. Cancer J. Sci. Am. 3(6), 371-372 (1997).
9. Olovnikov AM: A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of template margin biological significance of the phenomenon. J. Theor. Biol. 41(1), 181-190 (1973).
10. Watson JD: Origin of concatemeric T7 DNA. Nat. New Biol. 239 (94), 197-201 (1972).
11. Blackburn EH, Gall JG: A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena. J Mol. Biol. 120 (1), 33-53 (1978).
12. Dong CK, Masutomi K, Hahn WC: Telomerase: regulation, function and transformation. Crit. Rev. Oncol. Hematol. 54(2), 85-93 (2005).
13. Collins K: Structure and function of telomerase. Curr. Opin, Cell Biol. 8(3), 374-380 (1996).
14. Chatziantoniou VD: Telomerase: biological function and potential role in cancer management. Pathol. Oncol. Res. 7(3), 161-170 (2001).
15. Autexier C, Lue NF: The structure and function of telomerase reverse transcriptase. Annu. Rev. Biochem. 75, 493-517 (2006).
16. Blackburn EH: The end of the (DNA) line. Nat. Struct. Biol. 7(10), 847-850 (2000).
17. Shippen-Lentz D, Blackburn EH: Functional evidence for an RNA template in telomerase. Science 247(4942), 546-552 (1990).
18. Miller MC, Liu JK, Collins K: Template definition by Tetrahymena telomerase reverse transcriptase. Embo J 19(16), 4412-4422 (2000).
19. Lai CK, Miller MC, Collins K: Template boundary definition in Tetrahymena telomerase. Genes Dev. 16(4), 415-420 (2002).
20. Lamond AI: Tetrahymena telomerase contains an internal RNA template. Trends Biochem. Sci. 14(6), 202-204 (1989).
21. Blackburn EH: Telomeres: no end in sight. Cell 77(5), 621-623, (1994).
22. Greider CW, Blackburn EH; Identification of a specific telomere terminal transferase activity in Tetrahytnena extracts. Cell 43,(2 pt 1), 405-413 (1985).
23. Wright WE, Hayflick L: Nuclear control of cellular aging demonstrated by hybridization of anucleate and whole cultured normal humar fibroblasts. Exp. Cell Res. 96(1), 113-121 (1975).
24. Wright WE, Shay JW. Cellular senescence as a tumor-protection mechanism: the essential role ofcounting. Curr. Opin. Genet. Dev. 11(1) 98-103 (2001).
25. Hayflick L: The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614-636 (1965).
26. Bodnar AGI Ouellette M, Frolkis M et al.: Extension of life-span by introduction of telomerase into normal human cells. Science 279(5349), 349-352 (1998).
27. Casnpisi J, Min SH, Lim CS, Rubio M: Cellular senescence, cancer and aging: the telomere connection. Exp. Gerontol. 36(10), 1619-1637 (2001).
28. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur. J. Cancer 33(5), 787-791 (1997).
29. Shay JW, Wright WE: Telomerase therapeutics for cancer: challenges and new directions. Nat. Rev. Drug Discov. 5(7), 577-584 (2006).
30. Peng Y, Mian IS, Lue NF: Analysis of telomerase processivity: mechanistic similarity to HIV-1 reverse transcriptase and role in telomere maintenance. Mol. Cell 7(6), 1201-1211 (2001).
31. Lee SR, Wong JM, Collins K: Human telomerase reverse transcriptase motifs required for elongation of a telomeric substrate. J. Biol. Chem. 278(52), 52531-52536 (2003).
32. Bryan TM, Sperger JM, Chapman KB, Cech TR: Telomerase reverse transcriptase genes identified in Tetrahymena thermophila and Oxytricha trifallax. Proc. Natl Acad. Sci. USA 95(b), 8479-8484 (1998).
33. Friedman KL, Cech TR: Essential functions of amino-terminal domains in the yeast telomerase catalytic subunit revealed by selection for viable mutants. Genes Dev. 13(21), 2863-2874 (1999).
34. Friedman KL et al.: N-terminal domain of yeast telomerase reverse transcriptase. recruitment of Est3p to the telomerase complex. Mol. Biol. Cell 14(1), 1-13 (2003).
35. Lai CK, Mitchell JR, Collins K: RNA binding domain of telomerase reverse transcriptase. Mol. Cell. Biol. 21(4), 990-1000 (2001).
36. O'Connor CM, Lai CK, Collins, K: Two purified domains of telomerase reverse transcriptase reconstitute sequence-specific interactions with RNA. J. Biol. Chem. 280(17), 17533-17539 (2005).
37. Lai CK, Miller MC, Collins K: Roles for RNA in telomerase nucleotide and repeat addition processivity. Mol. Cell 11(6), 1673-1683 (2003).
38. Strahl C, Blackburn EH: The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res. 22(6), 893-900 (1994).
39. Fletcher TM, Cathers BE, Ravikumar KS, Mamiya BM, Kerwin SM: Inhibition of human telomerase by 7-deaza-2′-deoxyguanosine nucleoside triphosphate analogs: potent inhibition by 6-thio-7-deaza-2′-deoxyguanosine 5′-triphosphate. Bioorg. Chem. 29(1); 36-55 (2001).
40. Fletcher TM, Salazar M, Chen SF: Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates. Biochemistry 35(49), 15611-15617 (1996).
41. Gomez DE, Tejera AM, Olivero OA: Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythyraidine (AZT) treatment. Biochem. Biophys. Res. Commun. 246(1), 107-110 (1998).
42. Hájek M, Matulová N, Votruba I, Holý A, Tloust'ová E: Inhibition of human telomerase by diphosphates of acyclic nucleoside phosphonates. Biochem. Pharmacol. 70(6), 894-900 (2005).
43. Liu X, Takahashi H, Harada. Y et al.: 3′-Azido-2′,3′-dideoxynucleoside 5′-triphosphates inhibit telomerase activity in vitro, and the corresponding nucleosides cause telomere shortening in human HL60 cells. Nucleic Acids Res. 35(21), 7140-7149 (2007).
44. Murakami J, Nagai N, Shigemasa K, Ohama K: Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines. Eur. J. Cancer 35(6), 1027-1034 (1999).
45. Yamaguchi T, Kawarai M, Takeshita Y, Ishikawa F, Saneyoshi M: Inhibition of human telomerase by nucleotide analogues bearing a hydrophobic group. Nucleic Acids Symp. Ser. (44), 175-176 (2000).
46. Yamaguchi T, Liu Y, Ogawara T, Inomata M, Saneyoshi M: Telomerase inhibition by 3′-azido-2′, 3′-dideoxynucleoside 5′-triphosphates and telomere shortening in human cultured cells by the corresponding nucleosides. Nucleic Acids Symp. Ser. (Oxf.) (50), 271-272 (2006).
47. Yegorov YE, Chernov DN, Akimov SS et al.: Blockade of telomerase function by nucleoside analogs. Biochemistry (Mosc) 62(11), 1296-1305 (1997).
48. Yegorov YE, Chernov DN, Akimov SS, Bolsheva NL, Krayevsky AA, Zelenin AV: Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Lett. 389(2), 115-118 (1996).
49. Adotevi O, Pons FG, Langlade-Demoyen P: [Telomerase: a universal tumor antigen for anticancer immunotherapy]. Med. Sci. (Paris) 20(1), 19-21 (2004).
50. Carpenter EL, Vonderheide RH: Telomerase- based immunotherapy of cancer. Expert Opin. Biol. Ther. 6(10), 1031-1039 (2006).
51. Huo LF, Tang JW, Huang JJ et al.: Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell. Mol. Immunol. 3(1), 1-11 (2006).
52. Nguyen B, Elmore LW, Holt SE: Telomerase as a target for cancer immunotherapy. Cancer Biol. Ther. 2(2), 131-136 (2003).
53. Pang JX: [Human telomerase reverse transcriptase as a novel target for tumor immunotherapy]. Ai Zheng 22(8), 893-895 (2003).
54. Rousseau R, Soria JC: [Telomerase, a universal target in immunotherapy strategies against tumor?] Bull. Cancer 87(12), 895-901 (2000).
55. Sievers E, Albers P, Schmidt-Wolf IG, Märten A: Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. J. Urol. 171(1), 114-119 (2004).
56. Vonderheide RH, Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21(4), 674-679 (2002).
57. Gryaznov S, Pongracz K, Matray T et al.: Telomerase inhibitors - oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids 20(4-7), 401-410 (2001).
58. Gryaznov SM, Jackson S, Dikmen G et al.: Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent. Nucleosides Nucleotides Nucleic Acids 26(10-12), 1577-1579 (2007).
59. Herbert BS, Pongracz K, Shay JW, Gryaznov SM: Oligonucleotide N3′ → P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene 21(4), 638-642 (2002).
60. Pongracz K, Li S, Herbert BS et al.: Novel short oligonucleotide conjugates as inhibitors of human telomerase. Nucleosides Nucleotides Nucleic Acids 22(5-8), 1627-1629 (2003).
61. Pruzan R, Pongracz K, Gietzen K, Wallweber G, Gryaznov S: Allosteric inhibitors of telomerase: oligonucleotide N3′→P5′ phosphoramidates. Nucleic Acids Res. 30(2), 559-568 (2002).
62. Folini M, Pennati M, Zaffaroni N: Targeting human telomerase by antisense oligonucleotides and ribozymes. Curr. Med. Cbem. Anticancer Agents 2(5), 605-612 (2002).
63. Hayashidani Y, Hiyama E, Murakami Y, Sueda T: Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells. Hiroshima J. Med. Sci. 54(1), 21-27 (2005).
64. Li S, Nosrati M, Kashani-Sabet M: Knockdown of telomerase RNA using hammerhead ribozymes and RNA interference. Methods Mol. Biol. 405, 113-131 (2007).
65. Nosrati M, Li S, Bagheri S et al.: Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. Clin. Cancer Res. 10(15), 4983-4990 (2004).
66. Wan MS, Fell PL, Akhtar S: Synthetic 2′-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. Antisense Nucleic Acid Drug Dev. 8(4), 309-317 (1998).
67. Yokoyama Y, Wan X, Shinohara A, Takahashi Y, Tamaya T: Hammerhead ribozymes to modulate telomerase activity of endometrial carcinoma cells. Hum. Cell. 14(3), 223-231 (2001).
68. Zaffaroni N, Pennati M, Folini M: Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs. Methods Mol. Biol. 361, 239-263 (2007).
69. Zaffaroni N, Villa R, Pennati M, Folini M: Approaches for the inhibition of human telomerase based on the use of peptide nucleic acids and hammerhead ribozymes. Mini Rev. Med. Chem. 3(1), 51-60 (2003).
70. Gillis AJ, Schuller AP, Skordalakes E: Structure of the Tribolium castaneum telomerase catalytic subunit TERT. Nature 455(7213), 633-637 (2008).
71. Sarafianos SG, Clark AD Jr, Das K et al.: Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP- terminated DNA. Embo J. 21(23), 6614-6624 (2002).
72. Das K, Sarafianos SG, Clark AD Jr, Boyer PL, Hughes SH, Arnold E: Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J. Mol. Biol. 365(1), 77-89 (2007).